Related Experiment Video
Updated: Jun 5, 2026
11:17
Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
Published on: October 12, 2012
Bemiparin: pharmacological profile
1Pharmacology Department, School of Medicine, Autónoma University of Madrid, Madrid, Spain. carlosf.sanchezferrer@uam.es
Drugs
|December 18, 2010
Summary
Bemiparin, a second-generation low molecular weight heparin (LMWH), demonstrates potent antithrombotic activity with a favorable pharmacokinetic profile. Its low molecular weight and high anti-Xa to anti-IIa ratio offer advantages over unfractionated heparin.
Area of Science:
- Pharmacology
- Thrombosis Research
- Drug Development
Background:
- Bemiparin is a low molecular weight heparin (LMWH) used for thromboprophylaxis and deep vein thrombosis treatment.
- It is characterized by a low mean molecular weight (3.6 kDa) and a narrow molecular weight distribution.
- Bemiparin exhibits a high anti-Xa to anti-IIa activity ratio (8:1) compared to unfractionated heparin (1:1).
Purpose of the Study:
- To characterize the pharmacological profile of bemiparin.
- To compare its efficacy and pharmacokinetic properties with other heparinoids.
- To evaluate its antithrombotic potential.
Main Methods:
- Pharmacokinetic analysis following subcutaneous administration.
- Assessment of anti-Xa and anti-IIa activity.
- Evaluation of tissue factor pathway inhibitor (TFPI) release and activity.
- Comparison of dose-response curves with enoxaparin and tinzaparin.
Main Results:
- Bemiparin shows rapid absorption, high bioavailability (96%), and a long half-life (5.3 h).
- It exhibits dose-dependent anti-Xa activity and increases TFPI release and activity.
- Its pharmacokinetic profile and antithrombotic effects are superior to unfractionated heparin and comparable or better than other LMWHs.
Conclusions:
- Bemiparin possesses significant antithrombotic activity due to its high anti-Xa potency and TFPI-enhancing effects.
- Its favorable pharmacokinetic profile, including a long half-life and high bioavailability, supports its efficacy in thromboprophylaxis and treatment.
- Bemiparin represents an advanced LMWH with a potentially improved therapeutic index compared to unfractionated heparin.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:13Therapeutic Index
The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...